# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017554
Filing Date
2022-11-14
Accepted
2022-11-14 07:07:43
Documents
49
Period of Report
2022-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | plx-20220930x10q.htm iXBRL | 10-Q | 1014201
2 | EX-10.1 | plx-20220930xex10d1.htm | EX-10.1 | 565729
3 | EX-10.2 | plx-20220930xex10d2.htm | EX-10.2 | 57473
4 | EX-31.1 | plx-20220930xex31d1.htm | EX-31.1 | 10033
5 | EX-31.2 | plx-20220930xex31d2.htm | EX-31.2 | 10393
6 | EX-32.1 | plx-20220930xex32d1.htm | EX-32.1 | 6131
7 | EX-32.2 | plx-20220930xex32d2.htm | EX-32.2 | 6157
8 | GRAPHIC | plx-20220930x10q005.jpg | GRAPHIC | 113571
9 | GRAPHIC | plx-20220930x10q006.jpg | GRAPHIC | 100730
10 | GRAPHIC | plx-20220930x10q007.jpg | GRAPHIC | 35810
| Complete submission text file | 0001558370-22-017554.txt |  | 4990558

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
11 | EX-101.SCH | plx-20220930.xsd | EX-101.SCH | 30108
12 | EX-101.CAL | plx-20220930_cal.xml | EX-101.CAL | 35257
13 | EX-101.DEF | plx-20220930_def.xml | EX-101.DEF | 127889
14 | EX-101.LAB | plx-20220930_lab.xml | EX-101.LAB | 222057
15 | EX-101.PRE | plx-20220930_pre.xml | EX-101.PRE | 198750
43 | EXTRACTED XBRL INSTANCE DOCUMENT | plx-20220930x10q_htm.xml | XML | 435473

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 221380125
SIC: 2836 Biological Products, (No Diagnostic Substances)